The observation of clinical efficacy of rituximab in combination with DHAP chemotherapy in patients with relapsed non-hodgkin lymphoma / 肿瘤研究与临床

ABSTRACT

Objective To study the safety and efficacy of the combination of rituximab and DHAP chemotherapy in patients with relapsed non-Hodgkin lymphoma(NHL). Methods To choose 16 patients with relapsed B-cell NHL as research objects, they were divided into two groups treatment and control group. The treatment group(8 cases) received the combination of rituximab and DHAP chemotherapy; the control group (8 cases) received combination chemotherapy. The treatment was first infused a dose of rituximab (375 mg/m2) the day before receiving the DHAP chemotherapy, and such treatment being repeated for 4 ~ 6 times every other week. The DHAP chemotherapy lasts 4 ~ 6 cycles and twenty-one days in each cycle. The control group was primitively administrated 4 ~ 6 cycles of CHOP chemotherapy, methotrexate, Ara-C and etoposide as additional drug. Results The complete response and overall response rate were 75 % and 100 % while in the control group were 37.5 % and 62.5 %. The progression-free and overall survival was (18.3?5.4) months significantly higher than that of the control group [(4.7?2.8) months, P